1. Home
  2. SBR vs DRTS Comparison

SBR vs DRTS Comparison

Compare SBR & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sabine Royalty Trust

SBR

Sabine Royalty Trust

HOLD

Current Price

$72.50

Market Cap

1.0B

Sector

Energy

ML Signal

HOLD

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

HOLD

Current Price

$12.68

Market Cap

978.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBR
DRTS
Founded
1982
2015
Country
United States
Israel
Employees
N/A
121
Industry
Oil & Gas Production
Medical/Dental Instruments
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
978.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SBR
DRTS
Price
$72.50
$12.68
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
27.3K
812.0K
Earning Date
05-14-2026
05-18-2026
Dividend Yield
6.41%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$699.98
P/E Ratio
$12.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$65.15
$2.87
52 Week High
$84.39
$14.11

Technical Indicators

Market Signals
Indicator
SBR
DRTS
Relative Strength Index (RSI) 44.67 63.84
Support Level $72.41 $6.59
Resistance Level $73.00 N/A
Average True Range (ATR) 1.53 0.86
MACD 0.16 0.15
Stochastic Oscillator 33.99 70.26

Price Performance

Historical Comparison
SBR
DRTS

About SBR Sabine Royalty Trust

Sabine Royalty Trust formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Share on Social Networks: